
Osman SütcüoÄÄu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9017196/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Harmful consequences of COVID-19 fear in patients with cancer. BMJ Supportive and Palliative Care, 2023, 13, e102-e104.	0.8	17
2	Krukenberg Tumor Presentation of Recurrent Gallbladder Cancer After a Decade. Journal of Gastrointestinal Cancer, 2023, 54, 264-267.	0.6	2
3	Role of silymarin (<i>Silybum marianum</i>) in the prevention of colistin-induced acute nephrotoxicity in rats. Drug and Chemical Toxicology, 2022, 45, 568-575.	1.2	7
4	A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma. Journal of Oncology Pharmacy Practice, 2022, 28, 445-448.	0.5	5
5	Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment. Anti-Cancer Drugs, 2022, 33, e477-e485.	0.7	4
6	Pancreatic metastasis of invasive ductal breast carcinoma: A potential diagnostic pitfall. Breast Disease, 2022, 41, 187-189.	0.4	1
7	Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome. Current Medical Research and Opinion, 2022, 38, 579-586.	0.9	0
8	Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?. Journal of Clinical Oncology, 2022, , JCO2200047.	0.8	1
9	ROAR trial: which treatment is effective after progression?. Lancet Oncology, The, 2022, 23, e93.	5.1	0
10	Abscobal Effect of Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer. Journal of Clinical Oncology, 2022, 40, 2177-2178.	0.8	1
11	Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). Journal of Clinical Oncology, 2022, 40, 3898-3898.	0.8	5
12	Effect of serum uric acid level and Multinational Association for Supportive Care in Cancer risk score on febrile neutropenia mortality. Supportive Care in Cancer, 2021, 29, 1047-1053.	1.0	0
13	Panitumumab-induced trichomegaly. Current Problems in Cancer, 2021, 45, 100748.	1.0	0
14	Brigatinib-induced tuberculosis reactivation: A case report. Current Problems in Cancer, 2021, 45, 100738.	1.0	1
15	The role of serum albumin/globulin ratio in combination with prognostic risk indexes of febrile neutropenia. International Journal of Clinical Practice, 2021, 75, e14185.	0.8	2
16	Current status of biosimilars in Turkey: A survey among medical oncologists. Journal of Oncology Pharmacy Practice, 2021, , 107815522110316.	0.5	3
17	Bone marrow involvement in breast cancer. Current Problems in Cancer, 2021, 46, 100785.	1.0	0
18	Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncology, 2021, 17, 4447-4456.	1.1	26

Osman SütcüoÄŸlu

#	Article	IF	CITATIONS
19	Re: Post-progression outcomes of NSCLC patients with PD-L1 expression ≥50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 155, 294-295.	1.3	0
20	Dangerous interaction of bitter melon (Momordica charantia) with pazopanib: A case of acute pancreatitis. Journal of Oncology Pharmacy Practice, 2021, , 107815522110407.	0.5	1
21	Is it necessary to measure basal serum lipid levels in cancer patients prior to tamoxifen treatment?. Future Oncology, 2021, 17, 4823-4825.	1.1	1
22	Thirty-day mortality rates after immunotherapy initiation. Immunotherapy, 2021, 13, 1419-1426.	1.0	2
23	Herpes zoster infection of the breast. Breast Journal, 2020, 26, 2267-2268.	0.4	0
24	Is it possible to prevent contrast-induced nephropathy with dexpanthenol?. International Urology and Nephrology, 2019, 51, 1387-1394.	0.6	2
25	FP683BELIEFS AND ATTITUDES OF HEMODIALYSIS PATIENTS ON INFLUENZA VACCINATION. Nephrology Dialysis Transplantation, 2018, 33, i276-i276.	0.4	0
26	Primary renal neuroendocrine carcinoma. Journal of Cancer Research and Therapeutics, 2018, 14, 1444-1445.	0.3	3